CTLA4 and neoplasm: It has been recorded that a lack of efficacy of the anti-PD-1 and a modest clinical benefit of the anti-PD-L1 plus the anti-CTLA-4, reserved only to patients with a tumor mutational burden (TMB) more than 28 mut/Mb on circulating tumor DNA [8, 9].